《Trade Sales of European and North American Biopharma Companies 2016-2016》.pdf

January 2014 HBM Pharma/Biotech Report 2013 Trade Sales of European and North American Biopharma Companies 2005-2013 Key Findings  Total (upfront) transaction value reached $50.1 billion (vs. $43.6 billion in 2012), not including $12.4 billion value of deals that were announced, but not yet completed.  European deal volume more than doubled to $22.2 billion.  Four multi-billion deals completed (Onyx-Amgen $10.4 billion, Bausch Lomb-Valeant $8.7 billion, Elan-Perrigo $8.6 billion, Warner Chilcott-Actavis $8.5 billion).  Highest number of transactions (44) with an upfront of at least $100 million closed.  Premiums paid for public companies dropped to 32% (down from 52% in 2012 and 65% in 2011).  Mid-sized pharma and large biotech companies (mainly from the US) were the most important buyers, accounting for 80% of transaction volume.  Biopharma trade sales generated the best returns for US and European VCs (since 2005). About the HBM Pharma/Biotech MA Report The HBM Pharma/Biotech MA Report covers all completed trade sales of US, Canadian and European biotechnology and pharma (incl. generics and OTC) companies since 2005. The survey does not cover diagnostics, medical technology or life sciences tools services companies. Reverse mergers, minority investments and the purchase of assets or subsidiaries are not included in the survey. Acquisitions that were structured as mergers for tax or other reasons are included. Unless mentioned otherwise, transaction value is defined in this report as the upfront consideration in cash and/or shares. By contrast, the overall transaction value includes contingent (“biodollar”) payments linked to reaching certain milestones. Additional data such as investment by venture and private equity investors, exit multiples, stage of lead product etc were collected from various sources.